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with leukemia and extensive mucor infection was 
evatuated. 
Methods: Pre-B acute tymphobtastic teukemia was 
diagnosed in a 3-year-old mate in June 2002. Dur- 
ing induction treatment he presented with fever, 
periorbita[ swelling and a black lesion on his 
hard palate with subsequent pathology positive 
for invasive zygomycosis. MRI of the head and or- 
bits showed extensive bony destruction of frontat, 
maxittary, sphenoid and nasa[ bone with devet- 
opment of infittrating masses within the orbits. 
After extensive surgicat resection and debride- 
ment, he started on amphotericin B and shortty 
after switched to [iposoma[ amphotericin. MRI of 
the head showed progression of the infection and 
frontat robe cerebritis consistent with direct spread 
of the disease during treatment with high dose 
ambisome. The patient devetoped hypertension, 
etevated creatinine, pending renat faiture; treat- 
ment was switched from ambisome to posacona- 
zo[e on compassionate basis in December 2002, and 
7 months tater ambisome was added three times a 
week. The patient has continued on posaconazote 
for the past three years with days of interruptions 
due to chemotherapy, specificatty, vinca atkatoid. 
At 2 years into treatment he patient suffered 
teukemia retapse. 
Results: The patient was successfutty managed 
with high dose posaconazote 200mg three times 
a day for a period of 7 months with no major 
toxicity and stable disease in spite of being treated 
with high dose chemotherapy. Patient atso toter- 
ated the combination of ambisome three times a 
week with high dose posaconazo[e fairly wet[. In 
spite of retapse for teukemia and intensification 
of chemotherapy we were abte to continue ambi- 
some and posaconazote and keep the mucor under 
control MRI of head two years post treatment 
showed resotution of most of the previousty ab- 
normal findings, and a limited biopsy did not show 
any fungat etements. Currentty the patient is in 
second remission for teukemia nd on maintenance 
chemotherapy with 200 mg posaconazote wo times 
a day. 
Conclusion: Our case is a good exampte of a 
very compticated case of mucor infection with 
teukemia. We were abte to manage both issues of 
leukemia nd mucor with no major morbidity, with 
acceptabte [eve[ of toxicity of mitd to moderate 
facial disfiguration white keeping bilateral vision 
intact. 
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Purpose: Lipid-based amphotericin B formulations 
(LF) have been recommended to treat patients 
suffering from renat insufficiency. We report a 
prospective mutticentre survey to assess renat 
function in adult patients treated for funga[ in- 
fections with LF: Abe[cet ® (ABLC) and AmBisome ® 
(C-Amb). 
Description: 88 patients (43 F, 45 M) with a mean 
age of 49.64-14 years were inctuded and evatuabte 
for renat safety. 44% of patients had neutrope- 
nia <500mm 3. 60 patients were treated with ABLC 
(median dose: 4.8 mg/kg/day) and 28 patients with 
L-Amb (median dose: 3.3mg/kg/day). The mean 
duration of treatment was 13.5+8 days for ABLC 
and 15+11 days for L-Amb. 68% of the patients 
received 2 or more nephrotoxic drugs (72% for 
ABLC; 61% for L-Amb). 
Creatininemia 0~mo[/L) Median Creatinine clearance (m[/min) 
(range) Median (range) 
Baseline End of therapy Baseline End of therapy 
At[ patients 84.0 111.5 89.5 60.8 
(n=88) [38.0;465.0] [31.0;363.0] [17.2;172.2] [22.1;207.0] 
Abe[cet 81.3 115.0 94.6 89.5 
(n =60) [38.0; 465.0] [45.0; 241.6] [17.2; 172.2] [22.1; 183.0] 
Ambisome 88.8 106.0 85.2 71.6 
(n =28) [42.0; 356.0] [31.0; 363.0] [21.5; 145.6] [24.0; 207.0] 
Results: No significant change occurred be- 
tween median serum creatinine [eve[ at baseline 
(81.3 ~mo[/[ 38.0; 465.0], 88.8 ~mo[/[ 42.0; 356.0]) 
and at end of therapy (115.0 ~mo[/[ [45.0; 241.6], 
106.0 ~mo[/[ [31.0; 363.0]), respectively, for ABLC 
and L-Amb. No significant change occurred be- 
tween median creatinine clearance at baseline 
(94.6 and 85.2m[/mn) and end of therapy (60.4 
and 71.6 m[/mn), respectively, for ABLC and 
L-Amb. In the group of 26 patients with re- 
nat insufficiency prior to treatment, no signifi- 
cant difference was found between median crea- 
tinine [eve[ and creatinine clearance at baseline 
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(145.5~mot/t [88.0;465.0], 44.5mt/mn) and the 
end of the treatment (168.0~mot/t [66.0;363.0], 
39.8 mt/mn). 
Conclusion: This study showed treatment of pa- 
tients with LF had an exceLLent renal safety profile 
particuLarLy in patients either with a normal or 
altered renal function receiving combined nephro- 
toxic drugs. 
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Introduction: Severe sepsis, defined as a systemic 
response to infection with acute organ dysfunction, 
is associated with significant morbidity and mor- 
tality. Immunosuppression in hematologic patients 
resulting from chemotherapy Leads to severe infec- 
tion, which is a frequent cause of death. However, 
there is a paucity of data regarding the epidemi- 
otogy of severe sepsis in hematology malignancies. 
We conducted a study to determine estimates of 
the incidence and mortality of sepsis in this popu- 
Lation. 
Methods: ALL adult patients with hematologic 
malignancies admitted in our institution were 
prospectively observed. We analyzed the data of 
aLL episodes of sepsis which occurred during 4-year 
period including the foLLowing parameters: type of 
hematologic malignancy, chemotherapy regimens 
and setting, neutropenia duration, cLinicaL and mi- 
crobioLogicaL documentation and mortality. Sep- 
sis was defined according to the American CoL- 
Lege of Chest Physicians/Society of Critical Care 
Medicine. 
Results: Between January 2002 and September 
2005, from a total of 237 patients foLLowed, 
85 episodes of sepsis occurred in 68 (28%) patients. 
In these patients the type of underlying disease 
were: acute myetocytic Leukemia in 20 (29%), tym- 
phoma in 19 (28%), Leukemia acute Lymphocytic 
Leukemia in 8 (12%), chronic myetocytic Leukemia 
in 8 (12%), Hodgkin's disease in 6 (9%), myetoma 
in 3 (4%) and others 4 (6%).The median age in our 
population was 55 years. Among the patients with 
sepsis 21 (31%) had septicemia, 20 (29%) pneumo- 
nia, 16 (24%) both cLinicaL presentation, pneumonia 
plus septicemia and in 11 (16%) no infectious cause 
was found. Forty-one patients (60%) had a micro- 
bioLogicaLLy documented infection (MDI), 17 (25%) 
had only a cLinicaLLy documented infection (CDI) 
and 7 (10%) had fever of unknown origin (FUO). Of 
those patients with MDI, 35 cases (51%) had sep- 
ticemia, 6 (9%) had LocaLized infection without bac- 
teremia and 3 (5%) had a fungat MDI. The organism 
distribution was: Gram-negative baciLLi 21 (47%), 
Gram-positive 19 (43%), anaerobe 1 (4%) and fungus 
3 (6%). MortaLity from sepsis was 44% (30), of these, 
50% (15) were neutropenic when death occurred. 
The median age of the patients who died from 
sepsis was 49 years. 
Conclusions: We found that severe sepsis is a 
common and deadly complication in hematologic 
patients. The incidence and mortality in this pop- 
utation is not affected by age and is higher than 
was reported in the Literature. Advances in medical 
therapy and early diagnosis for these complicated 
patients could have a significant impact on cancer 
survivaL. 
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Background: Stenotrophomonas maltophilia (SM) 
is an emerging pathogen. We noticed in past years, 
increasing numbers of hematology patients with 
SM bacteremia in our hospitaL. Such patients are 
at high risk of SM infection but empiric antibiotic 
regimes often do not cover this muLti-resistant 
organism. 
ObJectives: We aim to characterize SM bacteremia 
in hematology patients; so as to identify those at 
risk of infection and modify practices to optimize 
care. 
Methods: Case notes of hematology patients with 
SM bacteremia between January 1999 and Decem- 
ber 2004 was reviewed retrospectively. CLinicaL 
characteristics, risk factors, manifestation of bac- 
teremia, and outcome were documented. 
Results: In the study period, SM bacteremia oc- 
curred in 36 hematology patients. Case notes 
were avaiLabLe for review in only 31 patients 
(20 males, 11 females; mean age 46 years). 
The most common hematoLogicaL disorder was 
acute myetoid Leukemia (67.7%). Other patients 
had tymphoma (9.7%), myetoma (3.2%), other 
Leukemia (12.9%) and aptastic anemia (3.2%). Mean 
Length of stay before bacteremia was 22 days. 
Five patients (I 6. I%) had bone marrow transplants, 
24 (77.4%) received chemotherapy; bacteremia 
